Publications
Detailed Information
In vitro and in vivo gene therapy with CMV vector-mediated presumed dog β-nerve growth factor in pyridoxine-induced neuropathy dogs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Jin-Young | - |
dc.contributor.author | Choi, Jung-Hoon | - |
dc.contributor.author | Shin, Il-Seob | - |
dc.contributor.author | Choi, Eun-Wha | - |
dc.contributor.author | Hwang, Cheol Yong | - |
dc.contributor.author | Lee, Sang-Koo | - |
dc.contributor.author | Youn, Hwa Young | - |
dc.date.accessioned | 2009-08-27 | - |
dc.date.available | 2009-08-27 | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | J Vet Sci 2008, 9, 367-373 | en |
dc.identifier.issn | 1229-845X | - |
dc.identifier.uri | http://www.vetsci.org/2008/abstract/367a.html | - |
dc.identifier.uri | https://hdl.handle.net/10371/7898 | - |
dc.description.abstract | Due to the therapeutic potential of gene therapy for
neuronal injury, many studies of neurotrophic factors, vectors, and animal models have been performed. The presumed dog β-nerve growth factor (pdβ-NGF) was generated and cloned and its expression was confirmed in CHO cells. The recombinant pdβ-NGF protein reacted with a human β-NGF antibody and showed bioactivity in PC12 cells. The pdβ-NGF was shown to have similar bioactivity to the dog β-NGF. The recombinant pdβ-NGF plasmid was administrated into the intrathecal space in the gene therapy group. Twenty-four hours after the vector inoculation, the gene therapy group and the positive control group were intoxicated with excess pyridoxine for seven days. Each morning throughout the test period, the dogs body weight was taken and postural reaction assessments were made. Electrophysiological recordings were performed twice, once before the experiment and once after the test period. After the experimental period, histological analysis was performed. Dogs in the gene therapy group had no weight change and were normal in postural reaction assessments. Electrophysiological recordings were also normal for the gene therapy group. Histological analysis showed that neither the axons nor the myelin of the dorsal funiculus of L4 were severely damaged in the gene therapy group. In addition, the dorsal root ganglia of L4 and the peripheral nerves (sciatic nerve) did not experience severe degenerative changes in the gene therapy group. This study is the first to show the protective effect of NGF gene therapy in a dog model. | en |
dc.description.sponsorship | This work was supported by the Brain Korea 21 program,
Korean Research Foundation Grant (KRF-2006-J02902), and the Research Institute of Veterinary Science, College of Veterinary Medicine, Seoul National University. | en |
dc.language.iso | en | en |
dc.publisher | 대한수의학회 = The Korean Society of Veterinary Science | en |
dc.subject | dog | en |
dc.subject | gene therapy | en |
dc.subject | in vitro | en |
dc.subject | in vivo | en |
dc.subject | nerve growth factor | en |
dc.subject | neuropathy | en |
dc.title | In vitro and in vivo gene therapy with CMV vector-mediated presumed dog β-nerve growth factor in pyridoxine-induced neuropathy dogs | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 정진영 | - |
dc.contributor.AlternativeAuthor | 최정훈 | - |
dc.contributor.AlternativeAuthor | 신일섭 | - |
dc.contributor.AlternativeAuthor | 최은화 | - |
dc.contributor.AlternativeAuthor | 황철용 | - |
dc.contributor.AlternativeAuthor | 이상구 | - |
dc.contributor.AlternativeAuthor | 윤화영 | - |
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.